Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 10, 2015; 6(5): 104-108
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.104
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.104
Current and future treatment of anaplastic lymphoma kinase-rearranged cancer
Luca Mologni, Molecular Oncology Lab, Department Health Sciences, University of Milano-Bicocca, 20900 Monza, Italy
Author contributions: Mologni L conceived the content and wrote the manuscript.
Supported by The Italian Association for Cancer Research, AIRC 2013 IG-14249.
Conflict-of-interest statement: The author declares no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Luca Mologni, PhD, Molecular Oncology Lab, Department Health Sciences, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy. luca.mologni@unimib.it
Telephone: +39-02-64488148 Fax: +39-02-64488363
Received: May 19, 2015
Peer-review started: May 20, 2015
First decision: July 10, 2015
Revised: July 16, 2015
Accepted: August 20, 2015
Article in press: August 21, 2015
Published online: October 10, 2015
Processing time: 146 Days and 13.4 Hours
Peer-review started: May 20, 2015
First decision: July 10, 2015
Revised: July 16, 2015
Accepted: August 20, 2015
Article in press: August 21, 2015
Published online: October 10, 2015
Processing time: 146 Days and 13.4 Hours
Core Tip
Core tip: In this Editorial article, I discuss the issue of anaplastic lymphoma kinase (ALK) driven cancer and its specific treatment with selective ALK tyrosine kinase inhibitors. The problem of acquired drug resistance is shortly reviewed and clinical data with novel investigational ALK inhibitors are presented. The possibility of specific combination therapies is briefly discussed.